LONDON, 10 August. - (ANA) - A drug that shows signs of halting Alzheimer’s disease could be prescribed within six months after US authorities approved it for “priority review”. 

 

Charities welcomed the decision to fast-track Aducanumab, which could be targeted at those with early signs of dementia. 

 

Alzheimer’s disease, the most common form of dementia in the UK, affects about 500,000 people here.  - (ANA) -

 

AB/ANA/10 August 2020 - - -